相似文献
1
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.
Haematologica. 2009 May;94(5):602-6. doi: 10.3324/haematol.2009.005702.
2
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
Haematologica. 2009 May;94(5):729-32. doi: 10.3324/haematol.2008.002063. Epub 2009 Mar 31.
3
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.
4
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Leuk Res. 2011 Feb;35(2):159-62. doi: 10.1016/j.leukres.2010.06.005. Epub 2010 Jul 1.
5
Management of older adults with myelodysplastic syndromes (MDS).
J Geriatr Oncol. 2018 Jul;9(4):302-307. doi: 10.1016/j.jgo.2017.12.002. Epub 2017 Dec 29.
6
Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes.
Rev Assoc Med Bras (1992). 2016 Oct;62 Suppl 1:25-28. doi: 10.1590/1806-9282.62.suppl1.25.
7
Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
Hematology Am Soc Hematol Educ Program. 2010;2010:325-9. doi: 10.1182/asheducation-2010.1.325.
8
The role of hematopoietic stem cell transplantation in myelodysplastic syndrome.
Oncology (Williston Park). 2005 Apr;19(4):533-42; discussion 542-4, 547-8.
9
Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes.
J Geriatr Oncol. 2014 Jul;5(3):299-306. doi: 10.1016/j.jgo.2014.02.002. Epub 2014 Mar 11.
10
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Cancer. 2017 Jul 15;123(14):2661-2670. doi: 10.1002/cncr.30632. Epub 2017 Mar 21.
引用本文的文献
1
Efficacy of Epoetin Alfa in Managing Symptomatic Anaemia in Low-Risk Myelodysplastic Syndromes: A Retrospective Analysis.
Cureus. 2024 Oct 27;16(10):e72460. doi: 10.7759/cureus.72460. eCollection 2024 Oct.
2
The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus.
J Cancer Res Clin Oncol. 2024 Feb 2;150(2):71. doi: 10.1007/s00432-023-05591-4.
3
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.
Leukemia. 2018 Dec;32(12):2648-2658. doi: 10.1038/s41375-018-0118-9. Epub 2018 Mar 30.
4
The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
Med Oncol. 2018 Feb 8;35(3):33. doi: 10.1007/s12032-018-1094-7.
5
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.
Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017046. doi: 10.4084/MJHID.2017.046. eCollection 2017.
6
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.
7
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.
Am J Hematol. 2014 May;89(5):509-16. doi: 10.1002/ajh.23675. Epub 2014 Feb 21.
8
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.
9
Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.
Haematologica. 2012 Apr;97(4):631-2. doi: 10.3324/haematol.2011.057323. Epub 2012 Jan 22.
10
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
J Clin Oncol. 2011 Jun 1;29(16):2240-6. doi: 10.1200/JCO.2010.31.3353. Epub 2011 May 2.
本文引用的文献
1
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
Haematologica. 2009 May;94(5):729-32. doi: 10.3324/haematol.2008.002063. Epub 2009 Mar 31.
2
Quality of life and satisfaction with outcome among prostate-cancer survivors.
N Engl J Med. 2008 Mar 20;358(12):1250-61. doi: 10.1056/NEJMoa074311.
3
Therapy-related leukemia and myelodysplasia: susceptibility and incidence.
Haematologica. 2007 Oct;92(10):1389-98. doi: 10.3324/haematol.11034.
4
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.
J Clin Oncol. 2007 Sep 20;25(27):4246-54. doi: 10.1200/JCO.2006.09.7865. Epub 2007 Aug 27.
5
Comprehensive geriatric assessment for older patients with cancer.
J Clin Oncol. 2007 May 10;25(14):1824-31. doi: 10.1200/JCO.2007.10.6559.
6
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.
Haematologica. 2006 Dec;91(12):1588-90.
7
Myelodysplastic syndromes in patients younger than age 50.
J Clin Oncol. 2006 Dec 1;24(34):5358-65. doi: 10.1200/JCO.2006.07.5598. Epub 2006 Nov 6.
8
Comorbid disease and cancer: the need for more relevant conceptual models in health services research.
J Clin Oncol. 2005 Oct 20;23(30):7399-404. doi: 10.1200/JCO.2004.00.9753.
9
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
J Clin Oncol. 2005 Oct 20;23(30):7594-603. doi: 10.1200/JCO.2005.01.7038. Epub 2005 Sep 26.
10
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.
Zotero 插件